Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinhua Qinggan Granules for mild COVID-19 in Pakistan
ChiCTR2000036871Phase 4Not yet recruiting
- Sponsor
- Center for Bioequivalence Studies and Clinical Research
- Start
- Apr 2020
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of jinhua qinggan granules in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Center for Bioequivalence Studies and Clinical Research. Primary endpoints: Change in clinical signs and symptoms and Time to negative SARS-CoV-2 RT-PCR. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
jinhua qinggan granules
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000036871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036871.